To include your compound in the COVID-19 Resource Center, submit it here.

Botox: Marketed to treat strabismus and blepharospasm associated with dystonia (disorder of the eye muscles that control blinking)

In a double-blind trial in 126 patients, 62% (40/64) of patients given Botox reported an improvement of at least

Read the full 197 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE